Objective: Hyperuricemia has been associated with high blood pressure (BP) values, diabetes mellitus, metabolic syndrome and chronic kidney disease (CKD). In the present study, we assessed the gender-related relationships between serum uric acid (SUA) and cardionephrometabolic variables in central and east European hypertensive patients.
INTRODUCTION
H yperuricemia is a frequent comorbidity in patients with hypertension and serum uric acid (SUA) values have been related to the development of fatal and nonfatal cardiovascular events [1] [2] [3] . SUA has been also related to the development of high blood pressure (BP) values [4] and a worse BP control [5] as well as to the occurrence of diabetes mellitus [6] , metabolic syndrome [7] , chronic kidney disease (CKD) [8] and preclinical target organ damage (TOD) [9] . However, frequently the studies reporting the aforementioned relationships suffered from limitations, including the presence of confounding factors, reverse causality phenomenon as well as the possibility that SUA represents only a marker of cardiovascular risk. A further limitation refers to the fact that only rarely the data were analyzed considering the possible effects of gender [9] [10] [11] . This applies in particular to the prevalence data in east European countries and to the relationships between SUA and the above-mentioned cardionephrometabolic disease.
In the present study, we sought to determine the genderrelated relationships between SUA and BP, metabolic and renal variables in treated hypertensive patients recruited in the Blood Pressure control rate and CArdiovascular Risk profilE (BP-CARE) study. This was a large cross-sectional study to assess BP control and quantify cardiovascular risk in individuals living in central and east Europe [12] , a geographic area with scanty data regarding SUA and cardionephrometabolic profile [13, 14] .
METHODS

Study population
The details of the BP-CARE study have been reported elsewhere [12] . Briefly, it consisted of a cohort of 8000 patients with a previous diagnosis of essential hypertension and under antihypertensive drug treatment recruited from nine different central and east European countries (Albania, Belarus, Bosnia, Czech Republic, Latvia, Romania, Serbia, Slovakia and Ukraine), with the involvement of about 800 physicians, both specialists and nonspecialists. Each physician was involved in the study by recruiting at least 10 consecutive men or women between 30 and 75 years of age with no exclusion criteria except for signing a written consent allowing the collection of data with the obligation of keeping them confidentially according to the European laws. The following data were collected in each patient: demographic and anthropometric data (weight, height and waist circumference -measured at the midpoint between lower ribs and the iliac crest -and BMI); personal history and documented clinical history with focus on previous documented cardiovascular events and/or documented cardiovascular and metabolic comorbidities, lifestyle habits and presence of cardiovascular risk factors such as sedentariety, cigarette smoking, excessive alcohol consumption, diabetes and dyslipidemia. Cardiovascular risk profile was quantified according to the European Society of Hypertension and the European Society of Cardiology (ESH/ESC) guidelines as well as hypertension grading (I-III) [15] .
In addition, the data collected included a careful assessment of the antihypertensive drugs used (type and dose) and laboratory test results (serum fasting blood glucose, total and HDL cholesterol, triglycerides, uric acid and creatinine). The laboratory tests were performed by accredited institutions which followed the procedures established by International Organization for Standardization (ISO) for collection, receipt, handling and analysis of the blood samples. BP was measured three times in a 15 min period via the sphygmomanometric technique with the patient in the sitting position for 15 min. Systolic and diastolic values were identified by the first and the fifth Korotkoff sounds, respectively. The mean of all the three measurements was used for the statistical analysis. Heart rate was measured after each BP measurement using the palpatory method over 30 s. Ambulatory BP data were analyzed if the equipment used was validated and set to obtain at least four readings per hour during day and three readings per hour during night with at least 70% of the BP readings accepted as valid by the software device. These technical requirements were satisfied in 1102 patients of the present analysis.
Regarding the end-point of the actual analysis, CKD was assessed by personal documented medical history or by an estimated glomerular filtration rate (GFR) below 60 ml/min per 1.73 m 2 using the Modification of Diet in Renal Disease formula [16] , diabetes mellitus was defined as personal documented medical history or as the documented use of antidiabetic drugs, whereas metabolic syndrome was detected according to the Adult Treatment Panel III criteria [17] . Finally, hyperuricemia was defined with two different cutoffs: the most commonly used with a SUA level greater than 6.0 mg/dl in women and greater than 7.0 mg/dl in men [18, 19] and a more aggressive one with a SUA level greater than 4.5 mg/dl in women and greater than 5.5 mg/dl in men [2, 3, 19] . Patients with a documented history of gout or under antihyperuricemic drugs were excluded from the analysis. The study protocol complies with the Declaration of Helsinki and it was approved by the Ethics Committee of the Institutions involved. All participants provided informed written consent after being informed of the study nature and purpose.
Data analysis
From the original cohort, patients without SUA measurements were excluded from the present analysis, reducing the present cohort to 3206 from the original 8000 patients' sample. Individual data were summed and expressed as means (AESD). The study population was subdivided into normal and hyperuricemic groups according to baseline SUA levels differently in men and women. Between-group differences were assessed by Student's t-test, Mann-Whitney test and x 2 tests (or Fisher's exact test whenever needed) for normally distributed, nonnormally distributed and categorical variables, respectively. Pearson's or Spearman's correlation coefficients were used, as appropriate, to test the association between variables. We performed logistic regression using the additive model and adjusting for covariates determined by stepwise regression. We used diabetes mellitus, metabolic syndrome, uncontrolled BP values, CKD and polytherapy as the dependent variables with SUA, age, sex, SBP, BMI, low-density lipoprotein (LDL) cholesterol, glucose and GFR as covariates. The same model was also repeated without GFR as covariate. In addition, in a similar model, the continuous SUA variables were replaced by the categorical definition of hyperuricemia (both with the commonly used and with the more aggressive cutoff). All analyses were performed with SAS software version 9.3 (SAS Institute Inc., Cary, North Carolina, USA) and a P value less than 0.05 was taken as the level of statistical significance. Table 1 reports the main demographic and clinical characteristics of the population as a whole and of the genderrelated subgroups. Patients showed a mean age of 60.0 AE 11 years, with an equal gender distribution (50.4% of men and 49.6% of women). SBP and DBP values amounted to 147.3 AE 18.9 and 87.9 AE 10.5 mmHg respectively, mean glucose was in the range of impaired fasting glucose (110.4 AE 37.2 mg/dl) whereas triglycerides, total and fractioned cholesterol levels showed fairly controlled values. Mean SUA levels amounted to 5.7 AE 1.9 mg/dl. Table 1 also reports the prevalence of the cardionephrometabolic variables. Thirty percentage of patients were diabetic with a high prevalence of metabolic syndrome (43%) and uncontrolled BP (58%) and a very high proportion of patients displaying a high or a very high cardiovascular risk (89%). CKD with a GFR less than 60 ml/min was detected in 2.7% of the population only.
RESULTS
Population characteristics
When patients were subdivided according to gender, women were older (58.6 AE 11.2 vs. 61.5 AE 10.6 years, P < 0.001) and showed a slightly greater burden of cardiovascular risk factors in comparison with men. Indeed, they showed significantly greater SBP, DBP, BMI, glucose, total and LDL cholesterol values. This was accompanied by a higher prevalence of metabolic syndrome, diabetes mellitus and uncontrolled BP but lower SUA levels (5.3 AE 1.9 vs. 6.0 AE 1.9 mg/dl, P < 0.001). Regarding treatment, only slight differences were observed between genders, as reported in Table 1 .
Normouricemic vs. hyperuricemic patients
When the whole population was divided accordingly to SUA values, a total of 826 patients were classified as hyperuricemic (25%) with SUA levels amounting to 7.97 AE 1.8 vs. normouricemic 4.90 AE 1.2 mg/dl, P <c0.001. These patients were older (61.8 AE 10.7 vs. 59.4 AE 11.0 years, P < 0.001) and showed a greater burden of cardiovascular risk factors (Table 2) . They also showed significantly greater SBP (both clinic and 24-h), BMI, glucose, total cholesterol and triglyceride levels. The prevalence of metabolic syndrome, diabetes mellitus, uncontrolled BP, very high cardiovascular risk and CKD was also higher. Significant differences in antihypertensive drug treatment were observed between groups with a greater percentage of patients taking diuretics and polytherapy, as reported in Table 2 . Diuretic treatment included hydrochlorothiazide at the dosage of 12.5-50 mg/ day in 71% of the patients assuming diuretics, followed by furosemide 10-20 mg/day in 16%, indapamide 1.25-2.5 mg and spironolactone (12.5-25 mg) in 8 and 5%, respectively. When the study population was analyzed taking into account the presence or absence of diuretic treatment, no significant difference was found in SUA levels between the two groups (patients under diuretic treatment 5.84 AE 2.0 mg/dl and patients without diuretic treatment 5.51 AE 1.9 mg/dl, P < 0.07).
Gender-specific analysis
When women were classified according to their SUA levels (Table 3) , 445 patients were classified as hyperuricemic (28%). This group was older (63.6 AE 10.1 vs. 60.6 AE 10.6 years, P < 0.001) and with BP values (both clinic and 24-h) superimposable to the normouricemic group. They displayed greater BMI, glucose and triglycerides. No difference in metabolic syndrome and rate of uncontrolled BP was found whereas a higher prevalence of diabetes, high cardiovascular risk and CKD was detected. When men were classified according to their SUA values, 381 patients were classified as hyperuricemic (23.5%). We found that the latter group was older (59.6 AE 10.9 vs. 58.3 AE 11.3 years, P ¼ 0.04) and displayed higher SBP and DBP, BMI, glucose, triglycerides and total cholesterol values (Table 4) . Hyperuricemic men showed a higher prevalence of metabolic syndrome, diabetes mellitus, high cardiovascular risk, higher rate of uncontrolled BP and CKD but not polytherapy.
Aggressive cutoff values
When analyses were repeated employing more aggressive hyperuricemic cutoff values (i.e. >5.5 mg/dl in men and 4.5 mg/dl in women), similar findings were observed. In the whole population, 1974 patients were classified as hyperuricemic (61%). These patients were older and showed a greater burden of cardiovascular risk factors (Table 5) . They also showed significantly greater clinic SBP and DBP, BMI, total cholesterol and triglyceride levels. The prevalence of metabolic syndrome, diabetes mellitus, very high cardiovascular risk and CKD was also higher whereas it was not the case for uncontrolled BP. Only slight differences in antihypertensive drug treatment were observed between groups with a greater percentage of patients taking diuretics and polytherapy. Similar data were found when the different variables were analyzed according to gender (data not shown).
Correlations and logistic regression analysis Table 6 shows the significant correlations observed in the population as a whole between cardionephrometabolic parameters and cardiovascular risk factors. With the exception of the rate of uncontrolled BP status, all the analyzed variables significantly correlated with SUA. When analysis was repeated separately by gender, in male patients SUA correlated with diabetes mellitus (r ¼ 0.08, P ¼ 0.001), metabolic syndrome (r ¼ 0.06, P ¼ 0.01), polytherapy (r ¼ 0.06, P ¼ 0.006), cardiovascular risk more than high (r ¼ 0.07, P ¼ 0.002) and CKD (r ¼ 0.23, P < 0.001). Finally in women, SUA correlated with diabetes mellitus (r ¼ 0.09, P < 0.001), metabolic syndrome (r ¼ 0.15, P < 0.001), polytherapy (r ¼ 0.52, P ¼ 0.03), cardiovascular risk more than high (r ¼ 0.09, P < 0.001) and CKD (r ¼ 0.38, P < 0.001).
Logistic regression analysis with the full model showed that none of the cardionephrometabolic variables displayed SUA as significant covariate, with the only exception of Data are shown as means AE standard deviation. For cardionephrometabolic variables and antihypertensive treatment, data are shown as percentages (in parentheses absolute numbers). ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; CKD, chronic kidney disease; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein; SUA, serum uric acid.
CKD (Fig. 1 ). More specifically, with a global r 2 value amounting to 0.12, age (b ¼ À0.03, P ¼ 0.04), glycemia (b ¼ 0.007, P ¼ 0.02) and SUA (b ¼ 0.27, P < 0.001) being the significant determinants of CKD.
Interestingly, when the analysis was repeated without GFR in the model, SUA was also as a significant determinant of metabolic syndrome. In the population as a whole with a global r 2 value of 0.22, gender (b ¼ 0.55, P < 0.001), LDL (b ¼ 0.08, P < 0.001), glycemia (b ¼ 0.04, P < 0.001), BMI (b ¼ 0.03, P < 0.001) and SUA (b ¼ 0.13, P < 0.001) being the significant determinants. Finally when this model was repeated replacing SUA with hyperuricemia, same results Data are shown as means AE standard deviation. For cardionephrometabolic variables and antihypertensive treatment, data are shown as percentages (in parentheses absolute numbers). ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; CKD, chronic kidney disease; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein; SUA, serum uric acid. were obtained with hyperuricemia being a significant determinant of CKD and metabolic syndrome. Classic cutoff values resulted in a b of 0.77 and 0.38 (P ¼ 0.01) for CKD and metabolic syndrome, respectively, whereas the more aggressive ones resulted in a b of 0.44 and 0.37, respectively (P ¼ 0.06).
DISCUSSION
Our study provides a number of important new findings. In the population of essential hypertensive patients living in central and east European countries, a high proportion of hyperuricemic patients was detected (25%). When this prevalence was compared with the one characterizing other countries it appears that substantial differences among different countries do exist [20] [21] [22] . This was particularly clear when the analysis was restricted to the hypertensive patients only. In an Italian population, a prevalence of 13.9% of hyperuricemic patients was observed [9, 20] , whereas in Japan, it amounted to 17.5% [23] reaching very high values (28.8%) in Nepalese hypertensive patients [24] . Many factors are potentially involved in these ethnic differences. First, genetic factors are involved in SUA metabolism regulation, with pathways, which remain still largely undefined [25] . Furthermore, life habit factors might also be responsible. This is particularly the case for overweight and obesity [26] and differences in the consumption of foods having high purine content [27] , alcohol [28] and soft drinks sweetened with fructose [29] , which are the main modifiable variables related to hyperuricemia development.
In our population, women displayed elevated SUA levels more frequently than men (28.0 vs. 23.5%). This has been previously reported in Italian hypertensive cohorts (12.8 and 15.2% for men and women, respectively) [8, 19] , whereas an opposite finding has been reported in the Japanese one (31.9 vs. 5.3%) [23] without significant differences in Nepalese hypertensive patients [24] . The genderrelated SUA difference we detected in our population is probably related to the fact that women were older and showed a slightly greater burden of cardiovascular risk factors compared with men. However, other factors may participate. Indeed, SUA levels appear to be more related to glycemia and diabetes mellitus in women than in men [12, 13] and to correlate more closely with BP levels and metabolic syndrome presence [7] . SUA levels have been associated with insulin resistance (both at clinical and preclinical level) [29, 30] as well as obesity [31] . In our population, women showed BMI values higher than men and this could be one of the potential factors responsible for the reported gender differences. Moreover, SUA metabolism is genetically controlled, and gender differences exist in gene function [32] . Finally, another possible explanation is the SUA increase reported after menopause [33] .
An additional result of the study was the finding that SUA levels were significantly related to all the analyzed cardionephrometabolic variables (except for uncontrolled BP) but resulted to be significantly determinant only in the case of renal dysfunction. Relationships between SUA and renal dysfunction have been extensively evaluated [34] and elevated values of SUA could not only determine renal damage throughout the deposition of uric acid into the renal tubules because of hyperuricosuria and crystal formation [35] but also through oxidative stress capable to trigger tubularinterstitial inflammation with an involvement of renal arterioles [36, 37] . On the other hand, hyperuricemia could also be the consequence of CKD as in this condition there is a lower renal elimination of uric acid with its accumulation in the blood [1, 3] . The data collected in this cross-sectional study do not allow to clarify this issue.
When the logistic regression model was repeated without GFR, SUA also resulted as a significant determinant of metabolic syndrome. Previous studies have shown that SUA is well associated with metabolic syndrome [38] and predicts its development in longitudinal studies [7] . The mechanism is well understood and includes oxidative stress, circulating nitric oxide (NO) concentration, insulin resistance and inflammation [39] [40] [41] . The fact that some of these pathways are shared with the renal damage is probably the reason why we were able to detect this relationship only when GFR is not included in the logistic regression model.
A final important result of our study refers to the cutoff values. When a more aggressive cutoff was used, we observed higher prevalence of hyperuricemia, whereas some cardionephrometabolic variables lost significance in the analysis comparing the normouricemic to the hyperuricemic state. Specifically, differences in uncontrolled BP lost significance in the whole population, this being the case for diabetes mellitus in women and for diabetes mellitus and uncontrolled BP in men. The main results of the logistic regression analysis, however, remained valid, suggesting that an aggressive cutoff does not add any additional information on the cardionephrometabolic variables evaluated.
Our study has some limitations but also elements of strength. One limitation is that the cross-sectional nature of the study prevented us to collect longitudinal information on the progression of cardionephrometabolic variables and association with SUA levels. Furthermore, we examined hypertensive patients that were under antihypertensive drug treatment and some specific classes of drugs may have affected the study results. However, the lack of significant differences in SUA levels in patients treated or not treated with diuretics seems to be against this possibility. Despite no specific inclusion criterion was defined, the BP-CARE population is a very high-risk one, with a very high percentage of comorbidities and an important prevalence of more than high cardiovascular risk. We cannot exclude that the analysis might be affected by this confounding factor with the inability to find some associations. Finally, we did not collect data on menopausal status leading to the impossibility to perform such an analysis in gender-related outcome. Study strengths include the large sample size of the population studied, which guarantees adequate power in identifying the association between analyzed variables and SUA levels.
In conclusion, our findings provide evidence of a high prevalence of hyperuricemia among hypertensive patients from central and east European countries. Furthermore, we provide conclusive demonstration on a large data base that gender-related differences in the association between SUA and cardiometabolic variables do exist. Finally, a further result relates to the independent and close association between SUA and renal alterations found in the BP-CARE population.
